WFDC2 and endometrial cancer: HE-4 has been mostly investigated in ovarian and endometrial cancer, but several studies have shown that HE-4 expression is increased in GC, particularly of diffuse-type, and its expression correlated with tumor size, stage, and survival [38,39].